Riferimento farmaci
Nivolumab
Nivolumab is a medicine in the class oncology. It is used for hodgkin lymphoma.
- Classe del farmaco: Oncology
- Indicato per: hodgkin lymphoma
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Codice ATC
- L01FF01
- Forme farmaceutiche comuni
- iniezione
- Dosaggi comuni
- 10 mg/ml, 40 mg/4 ml, 100 mg/10 ml
- Interazioni note
- 13 (Maggiore: 1 · Moderata: 7 · Minore: 5)
- Nomi commerciali
- 7
- Paesi e mercati
- 5
Per cosa si usa
Come agisce
Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Adjuvant Treatment of Melanoma: 240 mg IV q2Weeks or 480 mg IV q4Weeks
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause fetal harm: blocking PD-1 can break immune tolerance of the fetus; in monkeys it increased abortion and premature infant death. It crosses the placenta, mostly in the 2nd and 3rd trimesters. Check pregnancy status; use effective contraception during and for 5 months after.
- Allattamento
- Unsafe In one mother, milk levels were unexpectedly high and rose with repeated doses (an IgG4 antibody), though infant absorption is probably low. LactMed: avoid while breastfeeding. US label: do not breastfeed during treatment and for 5 months after the last dose.
Effetti indesiderati segnalati
- Rash
- Pruritus
- Cough
- Increased AST
- Hyponatremia
- Increased alkaline phosphatase
Chi deve prestare attenzione
- In combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to drug alone
- Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including immune-mediated pneumonitis
- May cause immune-mediated rash, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN);
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (13)
- Nivolumab + Thalidomide Major
- Dexamethasone + Nivolumab Moderate
- Dexamethasone-tobramycin + Nivolumab Moderate
- Efgartigimod / hyaluronidase sc + Nivolumab Moderate
- Efgartigimod alfa + Nivolumab Moderate
- Nivolumab + Ponesimod Moderate
- Nivolumab + Rozanolixizumab Moderate
- Nivolumab + Siponimod Moderate
- Amoxicillin-clavulanic acid + Nivolumab Minor
- Cefalexin + Nivolumab Minor
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Nivolumab: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 7 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Nivolumab used for?
Nivolumab is a medicine in the class oncology. It is used for Hodgkin lymphoma, Lung cancer, Melanoma, Mesothelioma, Renal cell carcinoma.
What side effects have been reported with Nivolumab?
Rash, Pruritus, Cough, Increased AST, Hyponatremia, Increased alkaline phosphatase.
Can Nivolumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: blocking PD-1 can break immune tolerance of the fetus; in monkeys it increased abortion and premature infant death. It crosses the placenta, mostly in the 2nd and 3rd trimesters. Check pregnancy status; use effective contraception during and for 5 months after. Breastfeeding: Unsafe. In one mother, milk levels were unexpectedly high and rose with repeated doses (an IgG4 antibody), though infant absorption is probably low. LactMed: avoid while breastfeeding. US label: do not breastfeed during treatment and for 5 months after the last dose.
What does Nivolumab interact with?
MediHelp lists 13 known interactions for Nivolumab. Major: 1 · Moderate: 7 · Minor: 5. The most serious include Thalidomide, Dexamethasone, Dexamethasone-tobramycin.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
